{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:37:25Z","timestamp":1793194645074,"version":"4.5.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41582-026-01261-4","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:56:21Z","timestamp":1788443781000},"page":"695-711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of complement and complement-targeted therapeutics in neurological diseases"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-1134","authenticated-orcid":false,"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan D.","family":"L\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"1261_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785\u2013797 (2010).","journal-title":"Nat. Immunol."},{"key":"1261_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nri3761","volume":"14","author":"M Kolev","year":"2014","unstructured":"Kolev, M., Friec, G. L. & Kemper, C. Complement \u2014 tapping into new sites and effector systems. Nat. Rev. Immunol. 14, 811\u2013820 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"1261_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nri.2017.74","volume":"17","author":"M Huse","year":"2017","unstructured":"Huse, M. Mechanical forces in the immune system. Nat. Rev. Immunol. 17, 679\u2013690 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"1261_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","volume":"12","author":"D Ricklin","year":"2016","unstructured":"Ricklin, D., Reis, E. S. & Lambris, J. D. Complement in disease: a defence system turning offensive. Nat. Rev. Nephrol. 12, 383\u2013401 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"1261_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.neuron.2012.03.026","volume":"74","author":"DP Schafer","year":"2012","unstructured":"Schafer, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691\u2013705 (2012).","journal-title":"Neuron"},{"key":"1261_CR6","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","volume":"131","author":"B Stevens","year":"2007","unstructured":"Stevens, B. et al. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164\u20131178 (2007).","journal-title":"Cell"},{"key":"1261_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","volume":"25","author":"MT Heneka","year":"2025","unstructured":"Heneka, M. T. et al. Neuroinflammation in Alzheimer disease. Nat. Rev. Immunol. 25, 321\u2013352 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1261_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1695461","volume":"16","author":"JY Chen","year":"2025","unstructured":"Chen, J. Y. et al. Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies. Front. Neurol. 16, 1695461 (2025).","journal-title":"Front. Neurol."},{"key":"1261_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/B978-0-323-90887-0.00014-6","volume":"214","author":"MC Dalakas","year":"2026","unstructured":"Dalakas, M. C. & Sp\u00e4th, P. J. Role of complement in neurologic autoimmunities: why need to target complement activation for effective immunotherapy. Handb. Clin. Neurol. 214, 65\u201383 (2026).","journal-title":"Handb. Clin. Neurol."},{"key":"1261_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","volume":"16","author":"MC Dalakas","year":"2020","unstructured":"Dalakas, M. C., Alexopoulos, H. & Spaeth, P. J. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat. Rev. Neurol. 16, 601\u2013617 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1261_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.mie.2021.01.020","volume":"649","author":"BA Spicer","year":"2021","unstructured":"Spicer, B. A. & Dunstone, M. A. Going full circle: determining the structures of complement component 9. Methods Enzymol. 649, 103\u2013123 (2021).","journal-title":"Methods Enzymol."},{"key":"1261_CR12","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","volume":"190","author":"CB Xie","year":"2020","unstructured":"Xie, C. B., Jane-Wit, D. & Pober, J. S. Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets. Am. J. Pathol. 190, 1138\u20131150 (2020).","journal-title":"Am. J. Pathol."},{"key":"1261_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neuron.2018.09.017","volume":"100","author":"EK Lehrman","year":"2018","unstructured":"Lehrman, E. K. et al. CD47 protects synapses from excess microglia-mediated pruning during development. Neuron 100, 120\u2013134.e6 (2018).","journal-title":"Neuron"},{"key":"1261_CR14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202304","volume":"219","author":"C Kurematsu","year":"2022","unstructured":"Kurematsu, C. et al. Synaptic pruning of murine adult-born neurons by microglia depends on phosphatidylserine. J. Exp. Med. 219, e20202304 (2022).","journal-title":"J. Exp. Med."},{"key":"1261_CR15","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.aaz2288","volume":"367","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. Microglia mediate forgetting via complement-dependent synaptic elimination. Science 367, 688\u2013694 (2020).","journal-title":"Science"},{"key":"1261_CR16","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.jbc.2021.101085","volume":"297","author":"CA Warwick","year":"2021","unstructured":"Warwick, C. A., Keyes, A. L., Woodruff, T. M. & Usachev, Y. M. The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain. J. Biol. Chem. 297, 101085 (2021).","journal-title":"J. Biol. Chem."},{"key":"1261_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-02024-8","volume":"17","author":"ND Schartz","year":"2020","unstructured":"Schartz, N. D. & Tenner, A. J. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J. Neuroinflammation 17, 354 (2020).","journal-title":"J. Neuroinflammation"},{"key":"1261_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41593-020-0624-8","volume":"23","author":"N Habib","year":"2020","unstructured":"Habib, N. et al. Disease-associated astrocytes in Alzheimer\u2019s disease and aging. Nat. Neurosci. 23, 701\u2013706 (2020).","journal-title":"Nat. Neurosci."},{"key":"1261_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40478-023-01526-9","volume":"11","author":"JM Lawrence","year":"2023","unstructured":"Lawrence, J. M., Schardien, K., Wigdahl, B. & Nonnemacher, M. R. Roles of neuropathology-associated reactive astrocytes: a systematic review. Acta Neuropathol. Commun. 11, 42 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"1261_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s42003-022-03237-8","volume":"5","author":"X Taylor","year":"2022","unstructured":"Taylor, X. et al. Activated endothelial cells induce a distinct type of astrocytic reactivity. Commun. Biol. 5, 282 (2022).","journal-title":"Commun. Biol."},{"key":"1261_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-immunol-101921-035639","volume":"41","author":"SS Bohlson","year":"2023","unstructured":"Bohlson, S. S. & Tenner, A. J. Complement in the brain: contributions to neuroprotection, neuronal plasticity, and neuroinflammation. Annu. Rev. Immunol. 41, 431\u2013452 (2023).","journal-title":"Annu. Rev. Immunol."},{"key":"1261_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200361","volume":"12","author":"J Oechtering","year":"2025","unstructured":"Oechtering, J. et al. Aberrant complement activation is associated with structural brain damage in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 12, e200361 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1094106","volume":"17","author":"R Evans","year":"2023","unstructured":"Evans, R. et al. Complement activation and increased anaphylatoxin receptor expression are associated with cortical grey matter lesions and the compartmentalised inflammatory response of multiple sclerosis. Front. Cell Neurosci. 17, 1094106 (2023).","journal-title":"Front. Cell Neurosci."},{"key":"1261_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200212","volume":"11","author":"J Oechtering","year":"2024","unstructured":"Oechtering, J. et al. Complement activation is associated with disease severity in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 11, e200212 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40478-018-0536-y","volume":"6","author":"I Michailidou","year":"2018","unstructured":"Michailidou, I. et al. Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. Acta Neuropathol. Commun. 6, 36 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"1261_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fimmu.2019.00362","volume":"10","author":"SM Carpanini","year":"2019","unstructured":"Carpanini, S. M., Torvell, M. & Morgan, B. P. Therapeutic inhibition of the complement system in diseases of the central nervous system. Front. Immunol. 10, 362 (2019).","journal-title":"Front. Immunol."},{"key":"1261_CR27","doi-asserted-by":"publisher","first-page":"9025","DOI":"10.1073\/pnas.86.22.9025","volume":"86","author":"DR Wren","year":"1989","unstructured":"Wren, D. R. & Noble, M. Oligodendrocytes and oligodendrocyte\/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody. Proc. Natl Acad. Sci. USA 86, 9025\u20139029 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1261_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.immuni.2019.12.004","volume":"52","author":"S Werneburg","year":"2020","unstructured":"Werneburg, S. et al. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease. Immunity 52, 167\u2013182.e7 (2020).","journal-title":"Immunity"},{"key":"1261_CR29","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.4049\/jimmunol.152.11.5477","volume":"152","author":"SJ Piddlesden","year":"1994","unstructured":"Piddlesden, S. J. et al. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152, 5477\u20135484 (1994).","journal-title":"J. Immunol."},{"key":"1261_CR30","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0002-9440(10)63466-9","volume":"163","author":"SH Weerth","year":"2003","unstructured":"Weerth, S. H., Rus, H., Shin, M. L. & Raine, C. S. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am. J. Pathol. 163, 1069\u20131080 (2003).","journal-title":"Am. J. Pathol."},{"key":"1261_CR31","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti, C. F. et al. A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 125, 1450\u20131461 (2002).","journal-title":"Brain"},{"key":"1261_CR32","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106\u20132112 (2004).","journal-title":"Lancet"},{"key":"1261_CR33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-017-1682-1","volume":"133","author":"Y Guo","year":"2017","unstructured":"Guo, Y. et al. Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathol. 133, 597\u2013612 (2017).","journal-title":"Acta Neuropathol."},{"key":"1261_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun, S. et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133, 349\u2013361 (2010).","journal-title":"Brain"},{"key":"1261_CR35","first-page":"4025","volume":"130","author":"T Chen","year":"2020","unstructured":"Chen, T. et al. Astrocyte\u2013microglia interaction drives evolving neuromyelitis optica lesion. J. Clin. Invest. 130, 4025\u20134038 (2020).","journal-title":"J. Clin. Invest."},{"key":"1261_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140966","volume":"131","author":"NE Propson","year":"2021","unstructured":"Propson, N. E., Roy, E. R., Litvinchuk, A., K\u00f6hl, J. & Zheng, H. Endothelial C3a receptor mediates vascular inflammation and blood\u2013brain barrier permeability during aging. J. Clin. Invest. 131, e140966 (2021).","journal-title":"J. Clin. Invest."},{"key":"1261_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0485-y","volume":"13","author":"F Wu","year":"2016","unstructured":"Wu, F. et al. Complement component C3a plays a critical role in endothelial activation and leukocyte recruitment into the brain. J. Neuroinflammation 13, 23 (2016).","journal-title":"J. Neuroinflammation"},{"key":"1261_CR38","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock, S. J. et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381, 614\u2013625 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1261_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock, S. J. et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann. Neurol. 93, 1053\u20131068 (2023).","journal-title":"Ann. Neurol."},{"key":"1261_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","volume":"139","author":"R H\u00f6ftberger","year":"2020","unstructured":"H\u00f6ftberger, R. et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 139, 875\u2013892 (2020).","journal-title":"Acta Neuropathol."},{"key":"1261_CR41","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/brain\/awaa102","volume":"143","author":"Y Takai","year":"2020","unstructured":"Takai, Y. et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 143, 1431\u20131446 (2020).","journal-title":"Brain"},{"key":"1261_CR42","doi-asserted-by":"publisher","unstructured":"Furlan, R. et al. Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis. Brain https:\/\/doi.org\/10.1093\/brain\/awaf345 (2025).","DOI":"10.1093\/brain\/awaf345"},{"key":"1261_CR43","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/ana.26226","volume":"90","author":"CW Keller","year":"2021","unstructured":"Keller, C. W. et al. Complement activation is a prominent feature of MOGAD. Ann. Neurol. 90, 976\u2013982 (2021).","journal-title":"Ann. Neurol."},{"key":"1261_CR44","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200340","volume":"12","author":"J Villacieros-\u00c1lvarez","year":"2025","unstructured":"Villacieros-\u00c1lvarez, J. et al. Complement activation profiles predict clinical outcomes in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol. Neuroimmunol. Neuroinflamm. 12, e200340 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100913","volume":"4","author":"M Spatola","year":"2023","unstructured":"Spatola, M. et al. Humoral signatures of MOG-antibody-associated disease track with age and disease activity. Cell Rep. Med. 4, 100913 (2023).","journal-title":"Cell Rep. Med."},{"key":"1261_CR46","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200293","volume":"11","author":"K Kaneko","year":"2024","unstructured":"Kaneko, K. et al. Different complement activation patterns following C5 cleavage in MOGAD and AQP4\u2212IgG+ NMOSD. Neurol. Neuroimmunol. Neuroinflamm. 11, e200293 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR47","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","volume":"20","author":"A Uzawa","year":"2024","unstructured":"Uzawa, A., Oertel, F. C., Mori, M., Paul, F. & Kuwabara, S. NMOSD and MOGAD: an evolving disease spectrum. Nat. Rev. Neurol. 20, 602\u2013619 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1261_CR48","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree, B. A. C. et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394, 1352\u20131363 (2019).","journal-title":"Lancet"},{"key":"1261_CR49","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee, A. et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 19, 402\u2013412 (2020).","journal-title":"Lancet Neurol."},{"key":"1261_CR50","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/1744666X.2022.2105205","volume":"18","author":"P Stathopoulos","year":"2022","unstructured":"Stathopoulos, P. & Dalakas, M. C. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders. Expert Rev. Clin. Immunol. 18, 933\u2013945 (2022).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"1261_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.09.004","volume":"6","author":"P Terroba-Navajas","year":"2025","unstructured":"Terroba-Navajas, P. et al. Humoral signatures of Caspr2-antibody spectrum disorder track with clinical phenotypes and outcomes. Med 6, 100515 (2025).","journal-title":"Med"},{"key":"1261_CR52","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000075","volume":"2","author":"P K\u00f6rtvelyessy","year":"2015","unstructured":"K\u00f6rtvelyessy, P. et al. Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 2, e75 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1212\/WNL.0b013e318228c136","volume":"77","author":"E Martinez-Hernandez","year":"2011","unstructured":"Martinez-Hernandez, E. et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 77, 589\u2013593 (2011).","journal-title":"Neurology"},{"key":"1261_CR54","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00401-022-02448-x","volume":"144","author":"O Chuquisana","year":"2022","unstructured":"Chuquisana, O. et al. Complement activation contributes to GAD antibody-associated encephalitis. Acta Neuropathol. 144, 381\u2013383 (2022).","journal-title":"Acta Neuropathol."},{"key":"1261_CR55","doi-asserted-by":"publisher","first-page":"153089","DOI":"10.1016\/j.imbio.2025.153089","volume":"230","author":"WM Zelek","year":"2025","unstructured":"Zelek, W. M. & Tenner, A. J. Complement therapeutics in neurodegenerative diseases. Immunobiology 230, 153089 (2025).","journal-title":"Immunobiology"},{"key":"1261_CR56","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41582-025-01073-y","volume":"21","author":"AJ Tenner","year":"2025","unstructured":"Tenner, A. J. & Petrisko, T. J. Knowing the enemy: strategic targeting of complement to treat Alzheimer disease. Nat. Rev. Neurol. 21, 250\u2013264 (2025).","journal-title":"Nat. Rev. Neurol."},{"key":"1261_CR57","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712\u2013716 (2016).","journal-title":"Science"},{"key":"1261_CR58","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat. Genet. 45, 1452\u20131458 (2013).","journal-title":"Nat. Genet."},{"key":"1261_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6295","volume":"9","author":"Q Shi","year":"2017","unstructured":"Shi, Q. et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice. Sci. Transl. Med. 9, eaaf6295 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1261_CR60","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.nbd.2019.03.003","volume":"127","author":"SE Parker","year":"2019","unstructured":"Parker, S. E. et al. Revisiting the role of the innate immune complement system in ALS. Neurobiol. Dis. 127, 223\u2013232 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1261_CR61","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jneuroim.2014.09.005","volume":"276","author":"S Mantovani","year":"2014","unstructured":"Mantovani, S. et al. Elevation of the terminal complement activation products C5a and C5b\u20139 in ALS patient blood. J. Neuroimmunol. 276, 213\u2013218 (2014).","journal-title":"J. Neuroimmunol."},{"key":"1261_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-10-119","volume":"10","author":"JD Lee","year":"2013","unstructured":"Lee, J. D. et al. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation 10, 119 (2013).","journal-title":"J. Neuroinflammation"},{"key":"1261_CR63","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaneurol.2023.2851","volume":"80","author":"A Genge","year":"2023","unstructured":"Genge, A. et al. Efficacy and safety of ravulizumab, a complement C5 inhibitor, in adults with amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 80, 1089\u20131097 (2023).","journal-title":"JAMA Neurol."},{"key":"1261_CR64","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.410390512","volume":"39","author":"CE Hafer-Macko","year":"1996","unstructured":"Hafer-Macko, C. E. et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol. 39, 625\u2013635 (1996).","journal-title":"Ann. Neurol."},{"key":"1261_CR65","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jneuroim.2008.05.028","volume":"201\u2013202","author":"HJ Willison","year":"2008","unstructured":"Willison, H. J. et al. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain\u2013Barr\u00e9 syndrome. J. Neuroimmunol. 201\u2013202, 172\u2013182 (2008).","journal-title":"J. Neuroimmunol."},{"key":"1261_CR66","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/brain\/awh231","volume":"127","author":"SK Halstead","year":"2004","unstructured":"Halstead, S. K. et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127, 2109\u20132123 (2004).","journal-title":"Brain"},{"key":"1261_CR67","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0165-5728(96)00133-6","volume":"71","author":"M Basta","year":"1996","unstructured":"Basta, M., Illa, I. & Dalakas, M. C. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain\u2013Barr\u00e9 syndrome, myasthenia gravis and dermatomyositis. J. Neuroimmunol. 71, 227\u2013229 (1996).","journal-title":"J. Neuroimmunol."},{"key":"1261_CR68","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/jns.12646","volume":"29","author":"S Kuwabara","year":"2024","unstructured":"Kuwabara, S. et al. Efficacy and safety of eculizumab in Guillain\u2013Barr\u00e9 syndrome: a phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial. J. Peripher. Nerv. Syst. 29, 339\u2013349 (2024).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1261_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/jns.70009","volume":"30","author":"QD Mohammad","year":"2025","unstructured":"Mohammad, Q. D. et al. Results from a phase 1 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ANX005, a C1q inhibitor, in patients with Guillain\u2013Barr\u00e9 syndrome. J. Peripher. Nerv. Syst. 30, e70009 (2025).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1261_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40478-016-0291-x","volume":"4","author":"R McGonigal","year":"2016","unstructured":"McGonigal, R. et al. C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy. Acta Neuropathol. Commun. 4, 23 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"1261_CR71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00401-025-02936-w","volume":"150","author":"F Stascheit","year":"2025","unstructured":"Stascheit, F. et al. Complement profiling of sural nerves in chronic-inflammatory demyelinating polyneuropathy. Acta Neuropathol. 150, 32 (2025).","journal-title":"Acta Neuropathol."},{"key":"1261_CR72","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/acn3.331","volume":"3","author":"I Quast","year":"2016","unstructured":"Quast, I., Keller, C. W., Hiepe, F., Tackenberg, B. & L\u00fcnemann, J. D. Terminal complement activation is increased and associated with disease severity in CIDP. Ann. Clin. Transl. Neurol. 3, 730\u2013735 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1261_CR73","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s13311-022-01221-y","volume":"19","author":"LA Querol","year":"2022","unstructured":"Querol, L. A. et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies. Neurotherapeutics 19, 864\u2013873 (2022).","journal-title":"Neurotherapeutics"},{"key":"1261_CR74","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200365","volume":"12","author":"L Querol","year":"2025","unstructured":"Querol, L. & Dalakas, M. C. The discovery of autoimmune nodopathies and the impact of IgG4 antibodies in autoimmune neurology. Neurol. Neuroimmunol. Neuroinflamm. 12, e200365 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR75","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s13311-022-01210-1","volume":"19","author":"MC Dalakas","year":"2022","unstructured":"Dalakas, M. C. Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti-B cell therapies. Neurotherapeutics 19, 741\u2013752 (2022).","journal-title":"Neurotherapeutics"},{"key":"1261_CR76","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001116","volume":"9","author":"MC Dalakas","year":"2022","unstructured":"Dalakas, M. C. IgG4-mediated neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies. Neurol. Neuroimmunol. Neuroinflamm. 9, e1116 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR77","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000119","volume":"2","author":"L Vlam","year":"2015","unstructured":"Vlam, L. et al. Complement activity is associated with disease severity in multifocal motor neuropathy. Neurol. Neuroimmunol. Neuroinflamm. 2, e119 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR78","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001107","volume":"9","author":"K Budding","year":"2022","unstructured":"Budding, K. et al. Anti-C2 antibody ARGX-117 inhibits complement in a disease model for multifocal motor neuropathy. Neurol. Neuroimmunol. Neuroinflamm. 9, e1107 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202200030","volume":"5","author":"JW Rumsey","year":"2022","unstructured":"Rumsey, J. W. et al. Classical complement pathway inhibition in a \u2018human-on-a-chip\u2019 model of autoimmune demyelinating neuropathies. Adv. Ther. 5, 2200030 (2022).","journal-title":"Adv. Ther."},{"key":"1261_CR80","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","volume":"16","author":"AM Fitzpatrick","year":"2011","unstructured":"Fitzpatrick, A. M. et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 16, 84\u201391 (2011).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1261_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16541","volume":"32","author":"K Budding","year":"2025","unstructured":"Budding, K. et al. Complement activation by IgM autoantibodies linked to immune-mediated neuropathies depends on C2. Eur. J. Neurol. 32, e16541 (2025).","journal-title":"Eur. J. Neurol."},{"key":"1261_CR82","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617746640","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas, M. C. Advances in the diagnosis, immunopathogenesis and therapies of IgM\u2013anti-MAG antibody-mediated neuropathies. Ther. Adv. Neurol. Disord. 11, 1756285617746640 (2018).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"1261_CR83","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/ana.20364","volume":"57","author":"R Lombardi","year":"2005","unstructured":"Lombardi, R. et al. IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Ann. Neurol. 57, 180\u2013187 (2005).","journal-title":"Ann. Neurol."},{"key":"1261_CR84","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200339","volume":"12","author":"JPM van de Mortel","year":"2025","unstructured":"van de Mortel, J. P. M. et al. The role of complement activation in IgM M-protein-associated neuropathies. Neurol. Neuroimmunol. Neuroinflamm. 12, e200339 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR85","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.1523\/JNEUROSCI.5623-06.2007","volume":"27","author":"V Ramaglia","year":"2007","unstructured":"Ramaglia, V. et al. The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J. Neurosci. 27, 7663\u20137672 (2007).","journal-title":"J. Neurosci."},{"key":"1261_CR86","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1523\/JNEUROSCI.18-17-06713.1998","volume":"18","author":"AT Dailey","year":"1998","unstructured":"Dailey, A. T., Avellino, A. M., Benthem, L., Silver, J. & Kliot, M. Complement depletion reduces macrophage infiltration and activation during Wallerian degeneration and axonal regeneration. J. Neurosci. 18, 6713\u20136722 (1998).","journal-title":"J. Neurosci."},{"key":"1261_CR87","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","volume":"18","author":"MC Dalakas","year":"2022","unstructured":"Dalakas, M. C. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert. Rev. Clin. Immunol. 18, 691\u2013701 (2022).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1261_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742","volume":"134","author":"HJ Kaminski","year":"2024","unstructured":"Kaminski, H. J., Sikorski, P., Coronel, S. I. & Kusner, L. L. Myasthenia gravis: the future is here. J. Clin. Invest. 134, e179742 (2024).","journal-title":"J. Clin. Invest."},{"key":"1261_CR89","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard","year":"2018","unstructured":"Howard, J. F. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann. N. Y. Acad. Sci. 1412, 113\u2013128 (2018).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1261_CR90","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1084\/jem.147.4.973","volume":"147","author":"VA Lennon","year":"1978","unstructured":"Lennon, V. A., Seybold, M. E., Lindstrom, J. M., Cochrane, C. & Ulevitch, R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147, 973\u2013983 (1978).","journal-title":"J. Exp. Med."},{"key":"1261_CR91","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","volume":"39","author":"K Sahashi","year":"1980","unstructured":"Sahashi, K., Engel, A. G., Lambert, E. H. & Howard, F. M. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 39, 160\u2013172 (1980).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1261_CR92","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/cells14100739","volume":"14","author":"A Martinez Salazar","year":"2025","unstructured":"Martinez Salazar, A., Mokhtari, S., Peguero, E. & Jaffer, M. The role of complement in the pathogenesis and treatment of myasthenia gravis. Cells 14, 739 (2025).","journal-title":"Cells"},{"key":"1261_CR93","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas, M. C. Immunotherapy in myasthenia gravis in the era of biologics. Nat. Rev. Neurol. 15, 113\u2013124 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1261_CR94","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/ene.15730","volume":"30","author":"F Stascheit","year":"2023","unstructured":"Stascheit, F. et al. Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis. Eur. J. Neurol. 30, 1409\u20131416 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1261_CR95","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1749-6632.2012.06783.x","volume":"1274","author":"LL Kusner","year":"2012","unstructured":"Kusner, L. L. & Kaminski, H. J. The role of complement in experimental autoimmune myasthenia gravis. Ann. N. Y. Acad. Sci. 1274, 127\u2013132 (2012).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1261_CR96","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","volume":"146","author":"BP Morgan","year":"2006","unstructured":"Morgan, B. P. et al. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin. Exp. Immunol. 146, 294\u2013302 (2006).","journal-title":"Clin. Exp. Immunol."},{"key":"1261_CR97","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/B978-0-323-98818-6.00023-6","volume":"195","author":"MC Dalakas","year":"2023","unstructured":"Dalakas, M. C. Autoimmune inflammatory myopathies. Handb. Clin. Neurol. 195, 425\u2013460 (2023).","journal-title":"Handb. Clin. Neurol."},{"key":"1261_CR98","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/1744666X.2022.2054803","volume":"18","author":"MC Dalakas","year":"2022","unstructured":"Dalakas, M. C. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert. Rev. Clin. Immunol. 18, 413\u2013423 (2022).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1261_CR99","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1093\/brain\/aww122","volume":"139","author":"R Lahoria","year":"2016","unstructured":"Lahoria, R., Selcen, D. & Engel, A. G. Microvascular alterations and the role of complement in dermatomyositis. Brain 139, 1891\u20131903 (2016).","journal-title":"Brain"},{"key":"1261_CR100","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas, M. C. Inflammatory muscle diseases. N. Engl. J. Med. 372, 1734\u20131747 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1261_CR101","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","volume":"403","author":"EE West","year":"2024","unstructured":"West, E. E., Woodruff, T., Fremeaux-Bacchi, V. & Kemper, C. Complement in human disease: approved and up-and-coming therapeutics. Lancet 403, 392\u2013405 (2024).","journal-title":"Lancet"},{"key":"1261_CR102","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-med-042921-102405","volume":"75","author":"T Miwa","year":"2024","unstructured":"Miwa, T., Sato, S., Golla, M. & Song, W.-C. Expansion of anticomplement therapy indications from rare genetic disorders to common kidney diseases. Annu. Rev. Med. 75, 189\u2013204 (2024).","journal-title":"Annu. Rev. Med."},{"key":"1261_CR103","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","volume":"114","author":"WM Zelek","year":"2019","unstructured":"Zelek, W. M., Xie, L., Morgan, B. P. & Harris, C. L. Compendium of current complement therapeutics. Mol. Immunol. 114, 341\u2013352 (2019).","journal-title":"Mol. Immunol."},{"key":"1261_CR104","unstructured":"Annexon announces positive topline results from real-world evidence study comparing ANX005 treatment to intravenous immunoglobulin (IVIg) or plasma exchange (PE) in a matched patient cohort for the treatment of Guillain\u2013Barr\u00e9 Syndrome (GBS). Annexon Inc. https:\/\/ir.annexonbio.com\/news-releases\/news-release-details\/annexon-announces-positive-topline-results-real-world-evidence\/ (16 December 2024)."},{"key":"1261_CR105","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1212\/WNL.0000000000210365","volume":"104","author":"L Querol","year":"2025","unstructured":"Querol, L. et al. Phase 2 efficacy and safety of riliprubart, a C1s-complement inhibitor, in chronic inflammatory demyelinating polyneuropathy (S16.009). Neurology 104, 2478 (2025).","journal-title":"Neurology"},{"key":"1261_CR106","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0031-6997(24)01437-6","volume":"52","author":"C Caliezi","year":"2000","unstructured":"Caliezi, C. et al. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52, 91\u2013112 (2000).","journal-title":"Pharmacol. Rev."},{"key":"1261_CR107","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000005","volume":"1","author":"M Levy","year":"2014","unstructured":"Levy, M. & Mealy, M. A. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol. Neuroimmunol. Neuroinflamm. 1, e5 (2014).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR108","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2026.2666430","volume":"18","author":"L Bracke","year":"2026","unstructured":"Bracke, L. et al. Structure\u2013function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody. MAbs 18, 2666430 (2026).","journal-title":"MAbs"},{"key":"1261_CR109","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","volume":"147","author":"I Van de Walle","year":"2021","unstructured":"Van de Walle, I. et al. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J. Allergy Clin. Immunol. 147, 1420\u20131429.e7 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1261_CR110","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"M Basta","year":"1994","unstructured":"Basta, M. & Dalakas, M. C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729\u20131735 (1994).","journal-title":"J. Clin. Invest."},{"key":"1261_CR111","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas, M. C. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993\u20132000 (1993).","journal-title":"N. Engl. J. Med."},{"key":"1261_CR112","doi-asserted-by":"publisher","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","volume":"10","author":"JW Lee","year":"2023","unstructured":"Lee, J. W. et al. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 10, e955\u2013e965 (2023).","journal-title":"Lancet Haematol."},{"key":"1261_CR113","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2147\/JBM.S431493","volume":"14","author":"M Oliver","year":"2023","unstructured":"Oliver, M. & Patriquin, C. J. Paroxysmal nocturnal hemoglobinuria: current management, unmet needs, and recommendations. J. Blood Med. 14, 613\u2013628 (2023).","journal-title":"J. Blood Med."},{"key":"1261_CR114","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","volume":"24","author":"DC Mastellos","year":"2024","unstructured":"Mastellos, D. C., Hajishengallis, G. & Lambris, J. D. A guide to complement biology, pathology and therapeutic opportunity. Nat. Rev. Immunol. 24, 118\u2013141 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1261_CR115","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/imr.12460","volume":"274","author":"J Dob\u00f3","year":"2016","unstructured":"Dob\u00f3, J., P\u00e1l, G., Cervenak, L. & G\u00e1l, P. The emerging roles of mannose-binding lectin-associated serine proteases (MASPs) in the lectin pathway of complement and beyond. Immunol. Rev. 274, 98\u2013111 (2016).","journal-title":"Immunol. Rev."},{"key":"1261_CR116","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","volume":"79","author":"N Collongues","year":"2019","unstructured":"Collongues, N., Ayme-Dietrich, E., Monassier, L. & de Seze, J. Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options. Drugs 79, 125\u2013142 (2019).","journal-title":"Drugs"},{"key":"1261_CR117","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard, J. F. et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 16, 976\u2013986 (2017).","journal-title":"Lancet Neurol."},{"key":"1261_CR118","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/B978-0-323-90887-0.00011-0","volume":"214","author":"A Evoli","year":"2026","unstructured":"Evoli, A., Gilhus, N. E. & Sanders, D. B. Immunotherapies in autoimmune neuromuscular junction disorders: acute and chronic management. Handb. Clin. Neurol. 214, 395\u2013415 (2026).","journal-title":"Handb. Clin. Neurol."},{"key":"1261_CR119","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-323-90887-0.00015-8","volume":"214","author":"I Lotan","year":"2026","unstructured":"Lotan, I., Anderson, M. & Levy, M. Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Handb. Clin. Neurol. 214, 255\u2013267 (2026).","journal-title":"Handb. Clin. Neurol."},{"key":"1261_CR120","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","volume":"19","author":"P Stathopoulos","year":"2022","unstructured":"Stathopoulos, P. & Dalakas, M. C. Evolution of anti-B cell therapeutics in autoimmune neurological diseases. Neurotherapeutics 19, 691\u2013710 (2022).","journal-title":"Neurotherapeutics"},{"key":"1261_CR121","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","volume":"17","author":"S Misawa","year":"2018","unstructured":"Misawa, S. et al. Safety and efficacy of eculizumab in Guillain\u2013Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 17, 519\u2013529 (2018).","journal-title":"Lancet Neurol."},{"key":"1261_CR122","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ana.24770","volume":"80","author":"D Mevorach","year":"2016","unstructured":"Mevorach, D. et al. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation. Ann. Neurol. 80, 708\u2013717 (2016).","journal-title":"Ann. Neurol."},{"key":"1261_CR123","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/B978-0-323-90887-0.00006-7","volume":"214","author":"CW Keller","year":"2026","unstructured":"Keller, C. W., Dalakas, M. C. & L\u00fcnemann, J. D. Intravenous immunoglobulin use in neurology. Handb. Clin. Neurol. 214, 173\u2013190 (2026).","journal-title":"Handb. Clin. Neurol."},{"key":"1261_CR124","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70251","author":"L Gerischer","year":"2025","unstructured":"Gerischer, L. et al. Inhibition of classical and alternative complement pathway by ravulizumab and eculizumab. Ann. Clin. Transl. Neurol. https:\/\/doi.org\/10.1002\/acn3.70251 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1261_CR125","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2665-9913(23)00003-6","volume":"5","author":"AL Mammen","year":"2023","unstructured":"Mammen, A. L. et al. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol. 5, e67\u2013e76 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1261_CR126","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2026.2333","author":"KG Gwathemey","year":"2026","unstructured":"Gwathemey, K. G. et al. Efficacy and safety of Gefurulimab in generalized myasthenia gravis. The PREVAIL phase 3 randomized clinical trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2026.2333 (2026).","journal-title":"JAMA Neurol."},{"key":"1261_CR127","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300571R","volume":"37","author":"L Gonz\u00e1lez-Del-Barrio","year":"2023","unstructured":"Gonz\u00e1lez-Del-Barrio, L. et al. MAP-2:CD55 chimeric construct effectively modulates complement activation. FASEB J. 37, e23256 (2023).","journal-title":"FASEB J."},{"key":"1261_CR128","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.imbio.2006.11.005","volume":"212","author":"R Flierman","year":"2007","unstructured":"Flierman, R. & Daha, M. R. The clearance of apoptotic cells by complement. Immunobiology 212, 363\u2013370 (2007).","journal-title":"Immunobiology"},{"key":"1261_CR129","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200542","volume":"13","author":"F Stascheit","year":"2026","unstructured":"Stascheit, F. et al. Aberrant complement activation is a prominent feature of chronic inflammatory demyelinating polyneuropathy. Neurol. Neuroimmunol. Neuroinflamm. 13, e200542 (2026).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR130","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00415-025-13181-2","volume":"272","author":"L M\u00fcller-Jensen","year":"2025","unstructured":"M\u00fcller-Jensen, L. et al. Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events. J. Neurol. 272, 459 (2025).","journal-title":"J. Neurol."},{"key":"1261_CR131","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200331","volume":"12","author":"F Stascheit","year":"2025","unstructured":"Stascheit, F. et al. Ravulizumab and efgartigimod in myasthenia gravis: a real-world study. Neurol. Neuroimmunol. Neuroinflamm. 12, e200331 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR132","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200270","volume":"11","author":"JD Lunemann","year":"2024","unstructured":"Lunemann, J. D. et al. Association of complement factors with disability progression in primary progressive multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 11, e200270 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR133","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200511","volume":"13","author":"MC Dalakas","year":"2026","unstructured":"Dalakas, M. C. Promising effects of CAR T-cell therapy in refractory stiff person syndrome and a hopeful future for all neuroautoimmunities. Neurol. Neuroimmunol. Neuroinflamm. 13, e200511 (2026).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1261_CR134","doi-asserted-by":"publisher","DOI":"10.1177\/17562864261429570","volume":"19","author":"MC Dalakas","year":"2026","unstructured":"Dalakas, M. C. The prospects of CAR T-cell therapies in changing the therapeutic algorithm of neurologic autoimmunities. Ther. Adv. Neurol. Disord. 19, 17562864261429570 (2026).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"1261_CR135","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/B978-0-323-90887-0.00012-2","volume":"214","author":"D Mougiakakos","year":"2026","unstructured":"Mougiakakos, D. & Dalakas, M. C. The future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology. Handb. Clin. Neurol. 214, 439\u2013451 (2026).","journal-title":"Handb. Clin. Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01261-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01261-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01261-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:01:38Z","timestamp":1793192498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01261-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":135,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1038\/s41582-026-01261-4","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"11 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}